Immunity to glycan α-Gal and possibilities for the control of COVID-19

"Despite the advances and potential impact that new vaccines represent for the prevention and control of COVID-19, interventions boosting the immune response to alpha-Gal with a broader and not pathogen-specific immunity may contribute not only to the control of COVID-19 but also to potential re-infections by SARS-CoV-2-related genetic variants or other pathogens that negatively affect the individual response to SARS-CoV-2."

Mots clés

alpha-gal covid-19 glycan immunity microbiota pandemic probiotic SARS-CoV-2 tick vaccine

Domaines

Immunologie

Sabine ROSSI : Connectez-vous pour contacter le contributeur

https://hal.inrae.fr/hal-03943467

Soumis le : mardi 17 janvier 2023-15:26:57

Dernière modification le : jeudi 11 janvier 2024-12:02:04

Dates et versions

hal-03943467 , version 1 (17-01-2023)

Identifiants

HAL Id : hal-03943467 , version 1
DOI : 10.2217/imt-2020-0247
PUBMED : 33307805
PUBMEDCENTRAL : PMC7735019
WOS : 000598402300001

Citer

José De La Fuente, Christian Gortázar, Alejandro Cabezas-Cruz. Immunity to glycan α-Gal and possibilities for the control of COVID-19. Immunotherapy, 2021, 13 (3), pp.185-188. ⟨10.2217/imt-2020-0247⟩. ⟨hal-03943467⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

ANSES BIPAR ENVA INRAE SAPS

13 Consultations

0 Téléchargements